Leukemia

Positive Phase 2 SY-1425 Results for AML and MDS

Positive Phase 2 SY-1425 Results for AML and MDS

Nancy Simonian, MD, discusses the results at ASH 2018.

New Standard of Care in CLL Proposed for Older Patients

New Standard of Care in CLL Proposed for Older Patients

By

Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.

The Biology and Genetics of Acute Leukemia: Two New Resources

The Biology and Genetics of Acute Leukemia: Two New Resources

Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.

Clinical Activity in Patients With MCL-1-Dependent R/R AML

Clinical Activity in Patients With MCL-1-Dependent R/R AML

Joshua Zeidner, MD, discusses stage 1 findings at the ASH 2018 meeting.

CAR-T and Ibrutinib: Better Together?

CAR-T and Ibrutinib: Better Together?

By

Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.

Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries

Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries

By

Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.

Updated Findings on Treatment Options for Patients With AML

Updated Findings on Treatment Options for Patients With AML

Rod A. Humerickhouse, MD, PhD, discusses findings from AbbVie at the ASH 2018 meeting.

Phase 3 MURANO Trial: Updated Data

Phase 3 MURANO Trial: Updated Data

Rod A. Humerickhouse, MD, PhD, discusses updated findings at the ASH 2018 meeting.

Second-Generation TKIs in Advanced CML: 7-Year Survival Rates

Second-Generation TKIs in Advanced CML: 7-Year Survival Rates

By

In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.

No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AML

No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AML

By

At first glance, the data on 695 patients with advanced myeloid leukemia (AML) seem to support a survival advantage of allogeneic hematopoietic cell transplantation (HCT) compared with no transplantation.

Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia

Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia

By

Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.

Prognostic and Therapeutic Significance of <i>TP53</i> Alterations in CLL

Prognostic and Therapeutic Significance of TP53 Alterations in CLL

By

There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.

Activation-Induced Cytidine Deaminase Transcripts Linked to More Aggressive CLL

Activation-Induced Cytidine Deaminase Transcripts Linked to More Aggressive CLL

By

AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.

Posttransplant AML Relapse Linked to Pathways Influencing Immune Function

Posttransplant AML Relapse Linked to Pathways Influencing Immune Function

By

There were no previously unknown AML-specific mutations or structural variations in immune-related genes among patients with AML who had undergone transplant.

Prototype Intervention Increased Adherence to TKIs in CML

Prototype Intervention Increased Adherence to TKIs in CML

By

A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

By

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

Enhancing the Delivery of Checkpoint Inhibitors in Patients with AML

Enhancing the Delivery of Checkpoint Inhibitors in Patients with AML

By

In mice models, the systemic delivery of blood platelets that were coated with anti-PD-1 antibodies and conjugated to HSCs halted the recurrence of leukemia.

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

By

Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.

Novel Regimen for High-Risk CLL Patients Seeking Transplantation

Novel Regimen for High-Risk CLL Patients Seeking Transplantation

By

A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.

Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments

Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments

By

There were 11 genes identified in BeatAML — called in at least 1% of patients — that were not originally recognized in previous AML sequencing studies.

Lenalidomide Induces Immunity, Produces Clinical Response in CLL

Lenalidomide Induces Immunity, Produces Clinical Response in CLL

By

Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.

Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment

Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment

By

High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

By

A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

By

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

By

The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

By

A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.

Duvelisib Delayed Progression in CLL/SLL: Study

Duvelisib Delayed Progression in CLL/SLL: Study

By

Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

By

Increased costs were found to be a result of more infections.

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

By

In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs